|Bid||1.7600 x 3200|
|Ask||1.8100 x 1100|
|Day's Range||1.7500 - 1.8398|
|52 Week Range||0.3500 - 5.2000|
|Beta (5Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2022 - Mar 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Aug 20, 2015|
|1y Target Est||11.33|
Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain Assets and Extensive Engagement with Stockholders Board Will Set Initial Distribution Date and Amount Once Potential Liability and Expenses Associated with Stockholder Litigation and Proxy Contest Are Known SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its intention to
Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.
A roindup of companies developing drugs and devices, inking new partnership deals, raising money, expanding facilities and more.